Audit: QRS - Chonluten for Health & Longevity

Audit conducted on 01/09/2026 02:44 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	At-a-glance traces to ER Conclusion; protocol cells to ER Therapeutic Protocol; gates to Key Interactions & Contraindications; markers to the ER monitoring table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Undefined; convention expects 10–30 days” and “Subcutaneous convention, not trial evidence” mirror the ER’s hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications remain in the stop gate; cautions remain cautions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No Benefit- or Risk-Modifying Factor content appears in any gate or tier list.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations or expert names present. Drug and peptide names (Bronchogen, Thymalin, Vilon, etc.) come from the same ER interaction bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same sober, evidence-limited register as the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Monitoring targets and protocol cells give the reader concrete, actionable structure.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Conventions are described, not prescribed.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or advisory constructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instance of “recommend”, “advise”, or “should”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are spelled out (e.g., “High-sensitivity C-reactive protein”, “Fractional exhaled nitric oxide”).
2.8	Information is presented in a concise and very compact manner	🟢	Gate items and tier entries are stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text search for “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal-range targets (hs-CRP below 0.5 mg/L, NLR 1.0–2.0) are aimed at optimizers, not general patients.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker monitoring panel plus daily qualitative tracking assumes high willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Spirometry and FeNO tracking are well beyond general-population expectations.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance names the product-quality hazard, the decision-relevant point for a self-sourcing audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Subcutaneous”, “hypersensitivity”, “immunosuppression”, “spirometry” used throughout; no consumer-grade substitutions.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings byte-identical to the template (lines 444, 484, 529, 554, 572, 591, 614, 618–620, 734).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; the repeatable marker_#_* and qualitative_item_# spans are correctly expanded to 1–9 and 1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website= spans (evidence_review, audit, full_review) and the entire style block are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No mapped ER section is empty; the empty Benefits “Low” tier is governed by the more specific rule 12.5, which forbids empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Synthetic tripeptide course”, “Oral capsule complex course”, “Best time of day” are the ER’s bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk entries reuse the ER’s #### headings verbatim; marker names match the ER table.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode emoji scan over the whole file returns no match; the ER’s tier emoji were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum consistent with the completeness rules (8.2, 14.2, 15.2); no explanatory prose survives.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment opens at line 2, closes at line 14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Byte inspection shows no leading/trailing whitespace; only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: chonluten_2026-0901-0036_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0901-0220, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: chonluten_2026-0901-0036_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys, including the tooling-added git_user and git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Chonluten for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Chonluten for Health & Longevity”, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/01/2026, correctly derived from 2026-0901-0220.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is byte-identical to the template apart from the three variable substitutions; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the four Conclusion paragraphs into the decision-relevant core: what it is, that nothing is measured in people, and that the hazard is the product.
7.2	[at_a_glance] is no longer than 60 words	🟢	54 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four clauses maps to a distinct Conclusion sentence (ER lines 414, 416, 418).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “three-amino-acid peptide”, “organ-targeted compounds”, “living person” are plain-language renderings.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items trace to the ER’s “Populations who should avoid Chonluten” list (ER lines 258–266).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine avoid-populations are present, and the two bullets the ER marks “Absolute contraindication” (checkpoint inhibitors, post-transplant immunosuppression) are both covered by the gate.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine <li> elements inside the stop_items span (lines 557–567).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes or trailing clauses; each item is a bare population descriptor.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 5 years”, “during and 6 months after”, “(Child-Pugh C)”, “below 30 mL/min/1.73 m²”, “(capsule preparation)” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names nine such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to the ER’s interaction bullets (ER lines 238–254).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s nine interaction bullets appear; the two the ER marks “Absolute contraindication” are correctly excluded and sit in the stop gate instead.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the caution_items span (lines 575–581).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution.”, “Monitor only.” and “Additive effect expected.” rationale sentences are all stripped; no dashes remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every example-drug parenthetical is retained; “omega-3 fatty acids” trimmed to “omega-3” under the permitted shortening allowance.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol section (ER lines 290–300).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two dosing routes (synthetic tripeptide, oral capsule complex) plus timing are the only directly actionable bullets; the remainder are modifiers, comparators, or attribution.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; labels are the ER’s bold labels verbatim, and the subs carry the ER’s convention-not-evidence caveat.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER describes exactly one time-to-effect aspect (Practical Considerations → “Time to effect”, ER line 345); it is the set that is used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	With a single aspect, the ordering constraint is satisfied trivially.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Sets 2 and 3 carry style="display: none" on both the cell and the spans, are empty, and are annotated with an explanatory HTML comment (lines 500–523).
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Undefined; convention expects 10–30 days” and the placebo-indistinguishability caveat both track ER line 345.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All five entries are the ER’s #### benefit headings (ER lines 144–160).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 531–547).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the five benefit names are carried; the ER’s supporting paragraphs and citations are dropped entirely.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in the benefits list.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	High, Medium and Low are all empty in the ER and all three spans carry style="display: none" with no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	The Low entry and all five Speculative entries are the ER’s #### headings (ER lines 192–216).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 593–608).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ER’s “Magnitude: Not quantified…” note and all mechanistic prose are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in the risks list.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	High and Medium are empty in the ER; both spans carry style="display: none" with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All nine rows derive from the ER Monitoring Protocol & Defining Success table (ER lines 377–385).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present, in ER order, with the ER’s optimal functional ranges preserved (including “No established target; track change from own baseline” for salivary sIgA).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 727 condenses the ER’s cadence prose: baseline, end of course, 8 weeks after stopping, then every 6–12 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the ER’s “Qualitative markers worth tracking alongside the labs” list (ER lines 389–394).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, condensed but complete.

Issues 01/09/2026 02:44

Pass rate 100.00%. No issues found.

Issues 01/09/2026 02:34

1. 4.5 — Exceeds one-page A4 budget: The sheet renders at roughly 1.7 A4 pages; per-section content was carried over from the ER without condensation, most visibly the trailing rationale clauses in the monitoring “why” column (lines 665-666, 677-678, 702-703, 726-727, 738-739), the three-sentence protocol and time-to-effect sub-cells (lines 454-456, 480-482, 498-500), the elaborated qualitative items (lines 761-762, 765-766, 769-770) and the full-prose contraindication items (lines 560-573).

Fixes 01/09/2026 02:34

1. 4.5 — Monitoring “why” clauses condensed: Stripped the trailing rationale clauses from five marker cells — “Directly tests the cytokine Chonluten suppresses in vitro” to “Tests the cytokine suppressed in cell studies”, “Detects blunted immune reserve, the main theoretical harm” to “Detects blunted immune reserve”, “Marks allergic airway inflammation and predicts who responds to airway therapy” to “Marks allergic airway inflammation”, “Non-invasive marker of airway inflammation, responsive within weeks” to “Non-invasive airway inflammation marker”, and “Mucosal immune defense, the function the compound claims to support” to “Mucosal immune defense”. Also shortened marker 5 and 9 “why” cells and marker 8’s target to “Track change from own baseline”, and trimmed the cadence sentence.

2. 4.5 — Protocol and time-to-effect subs shortened: Reduced the three-sentence protocol subs and the time-to-effect sub to one or two sentences each while keeping every ER-sourced parameter (20 mg vial, 200 µg / 30 days, 10–30 days, two to three courses a year, morning dosing, placebo-indistinguishable onset). Replaced the specialist term “chronopharmacology” with “dose-timing”.

3. 4.5 — Decision-gate items tightened: Rewrote all nine contraindications and three interaction items in compact form, preserving every qualifier — the 5-year cancer window, the 6-month checkpoint-inhibitor window, Child-Pugh C, the 30 mL/min/1.73 m² filtration threshold, and all named example drugs.

4. 4.5 — At-A-Glance and qualitative items compressed: Trimmed At-A-Glance from 56 to 54 words and shortened four qualitative assessment items to their key fact (e.g., “Breathlessness on a fixed exertion task, such as a set flight of stairs or a known walking route” to “Breathlessness on a fixed exertion task”).

Issues 01/09/2026 02:30

1. 8.4 — Drug lists added to contraindications: The stop items at lines 562 and 566 carry example-drug parentheticals (“(pembrolizumab, nivolumab, ipilimumab)” and “(tacrolimus, ciclosporin, mycophenolate)”) that appear nowhere in the ER’s “Populations who should avoid Chonluten” bullets; 8.5 permits only time windows, severity classes, thresholds and staging in this gate, and example drug lists are authorised for Key Interactions alone.

Fixes 01/09/2026 02:30

1. 8.4 — Drug lists removed from contraindications: Stripped the example-drug parentheticals from the two affected stop items, leaving “Immune checkpoint inhibitor therapy, during treatment and for 6 months afterward” and “Solid-organ transplant recipients on maintenance immunosuppression”. The ER-sourced time window and severity qualifiers were retained.

Issues 01/09/2026 02:26

1. 1.2 — Convention hedging dropped from Protocol: The ER frames every protocol parameter as convention rather than evidence (“Circulated subcutaneous conventions run 1-2 mg daily for 10-20 days”; “conventionally taken as 1-2 capsules of roughly 10 mg”), but the QRS Protocol panel presents both the synthetic tripeptide and oral capsule doses with no convention qualifier, reading as an established regimen.

Fixes 01/09/2026 02:26

1. 1.2 — Convention hedging restored in Protocol: Rewrote [action_1_sub] from “Subcutaneous, from a 20 mg freeze-dried vial.” to “Circulated subcutaneous convention, not trial evidence. From a 20 mg freeze-dried vial.”, and [action_2_sub] from “Cattle-lung extract preparation, once or twice daily with food” to “Cattle-lung extract preparation, conventionally taken once or twice daily with food”, matching the ER’s framing of every protocol parameter as practitioner convention rather than trial evidence.